Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 3Active not recruiting 2Approved for marketing 1

Sponsor Class

OTHER 29INDUSTRY 6NIH 5

Study Type

Observational 3Interventional 2Expanded_access 1

Sponsor

Cancer Type

NET 6Endocrine 6Gastrointestinal 1

Conditions

Neuroendocrine Tumors 6Gastro-enteropancreatic neuroendocrine tumor 3Somatostatin Receptor-positive Neuroendocrine Tumor 1Somatostatin Receptor-positive GEP-NET 1Pheochromocytoma 1Paraganglioma 1Glioblastoma 1Extensive Stage Small Cell Lung Cancer 1Advanced Neuroendocrine Neoplasm 1

Interventions

Everolimus 15surufatinib 7lutetium Lu 177 dotatate 6lanreotide 6amino-acid, glucose, and electrolyte solution 5Octreotide 5Sunitinib 4Data Collection 4pasireotide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3tislelizumab 2pembrolizumab 2fosbretabulin 2arginyllysine 2Temozolomide 2Paclitaxel 2PM 01183 2Irinotecan 2Carboplatin 264Cu-SARTATE 23-Iodobenzylguanidine 2toripalimab 1telotristat ethyl 1taxane 1repotrectinib 1pralsetinib 1pelcitoclax 1liposomal doxorubicin 1gadoteridol 1gadoterate meglumine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Neuroendocrine Tumors × lutetium Lu 177 dotatate × Clear all
NCT04727723 2026-05-04

REAL-LU

Novartis

Completed
164 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT03691064 2025-12-23

SALUS

Advanced Accelerator Applications

Active not recruiting
1,014 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05459844 2025-09-05

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Sinotau Pharmaceutical Group

Phase 3 Active not recruiting
196 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05816720 2023-04-18

Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)

Novartis

Completed
31 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01578239 2022-04-04

NETTER-1

Advanced Accelerator Applications

Phase 3 Completed
231 enrolled 16 charts 2 FDA
EndocrineNET

Neuroendocrine Tumors

NCT02705313 2018-04-09

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

Advanced Accelerator Applications

Approved for marketing
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡